FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2190682345> ?p ?o ?g. }

• W2190682345 abstract "ABSTRACT Aim: Anaplastic lymphoma kinase (ALK) positive NSCLC identifies a unique subset of patients who respond to treatment with crizotinib (Pfizer Inc, NY), an ALK receptor tyrosine kinase inhibitor. However, it is not well established whether ALK status is predictive of a better or a worse outcome for those who do not receive crizotinib. We performed a systematic review of recent literature on ALK positive NSCLC to answer this question. Methods: Ovid Medline and Embase databases were searched for publications on ALK-positive NSCLC until December 2013. Studies were included if outcomes for crizotinib naive patients were presented for either Progression-Free Survival (PFS) or Overall Survival (OS). For each study identified, 2 investigators independently extracted and tabulated relevant findings. Demographics, ALK status, type of diagnostic test, treatment received and response to treatment were noted. To determine if ALK status was prognostic, efficacy outcomes (PFS and / or OS) for ALK-positive patients were compared to ALK wild type (WT) patients. Results: Twenty one studies published between 2009 to 2013, with nearly 8000 screened NSCLC patients and 700 ALK-positive patients, met the selection criteria. All publications were retrospective in nature, majority reported single institution experiences, with a mix of completely resected early stage NSCLC and recurrent or advanced disease. The number of ALK-positive patients in studies determined by Fluorescent In Situ Hybridisation (FISH) ranged from 7 to 121 (mean = 32) and the number of ALK-positive patients in studies determined by non-FISH methods ranged from 3 - 39 (mean = 18). Enrichment strategies were commonly employed with predominantly adenocarcinomas being selected for ALK testing. PFS and / or OS for ALK-positive NSCLC patients did not demonstrate a favourable outcome and was similar or worse compared to EGFR WT/ ALK WT patients. Conclusions: This analysis of published retrospective studies in ALK-positive NSCLC, suggest that ALK-positivity is not a positive prognostic factor and does not confer a favourable outcome in absence of crizotinib therapy. Disclosure: J. Binko: Employee of Pfizer Oncology and holder of Pfizer stock; P. Delahoy: Employee of Pfizer Oncology and holder of Pfizer stock. M. Alam: Employee of Pfizer Oncology and holder of Pfizer stock." @default.
• W2190682345 created "2016-06-24" @default.
• W2190682345 creator A5040627519 @default.
• W2190682345 creator A5045842843 @default.
• W2190682345 creator A5052614434 @default.
• W2190682345 date "2014-09-01" @default.
• W2190682345 modified "2023-09-26" @default.
• W2190682345 title "Anaplastic Lymphoma Kinase (Alk) Positivity in Non Small Cell Lung Cancer (Nsclc) Has Similar or Worse Prognosis for Clinical Outcome As Alk Wild Type: a Systematic Review of Published Literature" @default.
• W2190682345 doi "https://doi.org/10.1093/annonc/mdu349.81" @default.
• W2190682345 hasPublicationYear "2014" @default.
• W2190682345 type Work @default.
• W2190682345 sameAs 2190682345 @default.
• W2190682345 citedByCount "0" @default.
• W2190682345 crossrefType "journal-article" @default.
• W2190682345 hasAuthorship W2190682345A5040627519 @default.
• W2190682345 hasAuthorship W2190682345A5045842843 @default.
• W2190682345 hasAuthorship W2190682345A5052614434 @default.
• W2190682345 hasBestOaLocation W21906823451 @default.
• W2190682345 hasConcept C117643217 @default.
• W2190682345 hasConcept C126322002 @default.
• W2190682345 hasConcept C143998085 @default.
• W2190682345 hasConcept C146357865 @default.
• W2190682345 hasConcept C151730666 @default.
• W2190682345 hasConcept C2776232967 @default.
• W2190682345 hasConcept C2776256026 @default.
• W2190682345 hasConcept C2778347629 @default.
• W2190682345 hasConcept C2779422266 @default.
• W2190682345 hasConcept C2779750558 @default.
• W2190682345 hasConcept C71924100 @default.
• W2190682345 hasConcept C86803240 @default.
• W2190682345 hasConceptScore W2190682345C117643217 @default.
• W2190682345 hasConceptScore W2190682345C126322002 @default.
• W2190682345 hasConceptScore W2190682345C143998085 @default.
• W2190682345 hasConceptScore W2190682345C146357865 @default.
• W2190682345 hasConceptScore W2190682345C151730666 @default.
• W2190682345 hasConceptScore W2190682345C2776232967 @default.
• W2190682345 hasConceptScore W2190682345C2776256026 @default.
• W2190682345 hasConceptScore W2190682345C2778347629 @default.
• W2190682345 hasConceptScore W2190682345C2779422266 @default.
• W2190682345 hasConceptScore W2190682345C2779750558 @default.
• W2190682345 hasConceptScore W2190682345C71924100 @default.
• W2190682345 hasConceptScore W2190682345C86803240 @default.
• W2190682345 hasLocation W21906823451 @default.
• W2190682345 hasOpenAccess W2190682345 @default.
• W2190682345 hasPrimaryLocation W21906823451 @default.
• W2190682345 hasRelatedWork W1996666174 @default.
• W2190682345 hasRelatedWork W2017789968 @default.
• W2190682345 hasRelatedWork W2122978062 @default.
• W2190682345 hasRelatedWork W2494524177 @default.
• W2190682345 hasRelatedWork W2508425825 @default.
• W2190682345 hasRelatedWork W2604868172 @default.
• W2190682345 hasRelatedWork W2740325956 @default.
• W2190682345 hasRelatedWork W2740331593 @default.
• W2190682345 hasRelatedWork W2741015391 @default.
• W2190682345 hasRelatedWork W2767293941 @default.
• W2190682345 hasRelatedWork W2778146565 @default.
• W2190682345 hasRelatedWork W2795514639 @default.
• W2190682345 hasRelatedWork W2804461875 @default.
• W2190682345 hasRelatedWork W2890742011 @default.
• W2190682345 hasRelatedWork W2947178545 @default.
• W2190682345 hasRelatedWork W2983232492 @default.
• W2190682345 hasRelatedWork W3016409569 @default.
• W2190682345 hasRelatedWork W3025108658 @default.
• W2190682345 hasRelatedWork W3091837880 @default.
• W2190682345 hasRelatedWork W3202501073 @default.
• W2190682345 isParatext "false" @default.
• W2190682345 isRetracted "false" @default.
• W2190682345 magId "2190682345" @default.
• W2190682345 workType "article" @default.